{"id":"hal-0-2-with-illumination","safety":{"commonSideEffects":[{"rate":"null","effect":"Skin photosensitivity"},{"rate":"null","effect":"Skin burning sensation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"HAL is a photosensitizer that, upon illumination, generates reactive oxygen species that destroy cancer cells.","oneSentence":"Photodynamic therapy with aminolevulinic acid","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:40:39.462Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis"}]},"trialDetails":[{"nctId":"NCT01256424","phase":"PHASE2","title":"Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia","status":"COMPLETED","sponsor":"Photocure","startDate":"2011-04","conditions":"Cervical Intraepithelial Neoplasia","enrollment":262}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"HAL 0.2% with illumination","genericName":"HAL 0.2% with illumination","companyName":"Photocure","companyId":"photocure","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Photodynamic therapy with aminolevulinic acid Used for Actinic keratosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}